Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211416 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
A Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 2
- Study locations
NCT03211416 is a Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 37 participants, above the 25-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target (48% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03211416, a Phase 1 study of Advanced Adult Hepatocellular Carcinoma and Stage IIIA Hepatocellular Carcinoma, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Sorafenib Tosylate
Study Locations (2)
Illinois
- Robert H Lurie Comprehensive Cancer Center - Chicago
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-12-07 |
| Est. Completion | 2025-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211416
The ClinicalTrials.gov registry entry for NCT03211416 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 25-participant average among 3 other Advanced Adult Hepatocellular Carcinoma trials with a reported enrollment target (48% higher). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Advanced Adult Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03211416 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT03211416 about?
NCT03211416 is a clinical study titled "Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer". This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, su...
What is the current status of trial NCT03211416?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2017-12-07. Estimated completion is 2025-08-15.
What conditions does trial NCT03211416 study?
This clinical trial studies the following conditions: Advanced Adult Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03211416?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT03211416?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03211416 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
COMPLETED · Phase 1
-
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
COMPLETED · NA
Explore more on PlainTrial
Advanced Adult Hepatocellular Carcinoma
All registered trials for this condition
Stage IIIA Hepatocellular Carcinoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.